Jen Wieczner

Trading At The NYSE As  Valeant Shares Halted Ahead of News Announcement

Here’s Why Moody’s Just Downgraded Valeant

/2016/04/01/valeant-default-moodys/

Doctors Without Borders Protests High Cost Of Vaccines

Pfizer Just Got Pranked Big Time Before April Fool’s Day Even Started

/2016/03/31/pfizer-drug-prices-april-fools/

The ‘Trump Dump’ App Has Been Downloaded More Than One Million Times

/2016/03/31/donald-trump-dump-app/

This Hacker Sent Nazi Flyers to Thousands of Printers In Internet of Things ‘Experiment

/2016/03/29/hack-printers-internet-of-things/

This Stock ​Is​ Soaring Because the FBI Cracked the San Bernardino Shooter’s iPhone

/2016/03/29/fbi-iphone-stock-suncorp/

U.S. Government Asked Amazon to Lie in Staples-Office Depot Merger Case, Judge Says

/2016/03/25/amazon-staples-office-depot/

Uber and Blade Will Fly You to Coachella in a Helicopter for about $4,000

/2016/03/25/uber-blade-coachella-helicopter/

Why the IRS’s Technology Nightmare Is Far From Over

/2016/03/25/irs-technology-taxes/

Valeant Infighting Is Getting Nasty

/2016/03/21/valeant-howard-schiller/

Last Day Of Trading At The NYSE As US Stocks Edge Lower, Pulling S&amp;P 500 Into Red For The Year

The S&P 500 Just Broke Into Positive Territory for 2016

/2016/03/18/stock-market-today-sp-500/

Key Speakers At The Bloomberg Markets Most Influential Summit

This Valeant Investor Is In Even Bigger Trouble than Bill Ackman

/2016/03/18/valeant-stock-sequoia-fund/

J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)

Valeant CEO Promises Company Won’t Go Bankrupt in Staff Memo

/2016/03/18/valeant-stock-bankrupt/

Why Bill Ackman Ought to Buy Warren Buffett a Coke

/2016/03/15/coca-cola-stock/

Key Speakers At The 2015 Milken Conference

Herbalife’s CEO Needs More Security Than Donald Trump

/2016/03/15/herbalife-security-warren-buffett/

Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview